Stocks and Investing
Stocks and Investing
Fri, April 29, 2022
[ Fri, Apr 29th 2022
] - WOPRAI
[ Fri, Apr 29th 2022
] - WOPRAI
[ Fri, Apr 29th 2022
] - WOPRAI
[ Fri, Apr 29th 2022
] - WOPRAI
[ Fri, Apr 29th 2022
] - WOPRAI
Thu, April 28, 2022
[ Thu, Apr 28th 2022
] - WOPRAI
[ Thu, Apr 28th 2022
] - WOPRAI
[ Thu, Apr 28th 2022
] - WOPRAI
[ Thu, Apr 28th 2022
] - WOPRAI
[ Thu, Apr 28th 2022
] - WOPRAI
[ Thu, Apr 28th 2022
] - WOPRAI
[ Thu, Apr 28th 2022
] - WOPRAI
[ Thu, Apr 28th 2022
] - WOPRAI
[ Thu, Apr 28th 2022
] - WOPRAI
[ Thu, Apr 28th 2022
] - WOPRAI
[ Thu, Apr 28th 2022
] - WOPRAI
[ Thu, Apr 28th 2022
] - WOPRAI
[ Thu, Apr 28th 2022
] - WOPRAI
[ Thu, Apr 28th 2022
] - WOPRAI
[ Thu, Apr 28th 2022
] - WOPRAI
[ Thu, Apr 28th 2022
] - WOPRAI
[ Thu, Apr 28th 2022
] - WOPRAI
[ Thu, Apr 28th 2022
] - WOPRAI
[ Thu, Apr 28th 2022
] - WOPRAI
[ Thu, Apr 28th 2022
] - WOPRAI
[ Thu, Apr 28th 2022
] - WOPRAI
[ Thu, Apr 28th 2022
] - WOPRAI
[ Thu, Apr 28th 2022
] - WOPRAI
[ Thu, Apr 28th 2022
] - WOPRAI
Evan Seigerman Maintained (AMGN) at Hold with Decreased Target to $243 on, Apr 28th, 2022
Evan Seigerman of BMO Capital, Maintained "Amgen Inc." (AMGN) at Hold with Decreased Target from $263 to $243 on, Apr 28th, 2022.
Evan has made no other calls on AMGN in the last 4 months.
There are 5 other peers that have a rating on AMGN. Out of the 5 peers that are also analyzing AMGN, 4 agree with Evan's Rating of Hold. Following are those relevant analyst calls for the last 4 months
- Carter Gould of "Barclays" Maintained at Hold with Increased Target to $236 on, Tuesday, April 12th, 2022
- Matthew Harrison of "Morgan Stanley" Maintained at Hold with Decreased Target to $237 on, Tuesday, April 12th, 2022
- Mohit Bansal of "Wells Fargo" Maintained at Hold with Increased Target to $250 on, Wednesday, February 9th, 2022
- Geoff Meacham of "B of A Securities" Downgraded from Strong Buy to Hold and Decreased Target to $255 on, Wednesday, January 5th, 2022
This is the rating of the analyst that currently disagrees with Evan
- Jay Olson of "Oppenheimer" Maintained at Buy with Increased Target to $285 on, Wednesday, February 9th, 2022
Contributing Sources